Lupus
| Agente | Año | Tipo de estudio | Pacientes (n) | TR (n) | Casos adversos | Recaída | Muertes |
|---|---|---|---|---|---|---|---|
| INFLIXIMAB | 2004 |
D |
6 |
6 |
3 |
3 |
0 |
2007 |
D |
1 |
1 |
0 |
0 |
0 |
|
2007 |
D |
1 |
1 |
0 |
0 |
0 |
|
2007 |
D |
1 |
1 |
0 |
0 |
0 |
|
| Total | 9 |
9 |
3 |
3 |
0 |
||
| RITUXIMAB | 2007 |
B |
14 |
9 |
NR |
0 |
0 |
2005 |
C |
13 |
9 |
5 |
2 |
2 |
|
2005 |
C |
10 |
7 |
5 |
3 |
0 |
|
2006 |
C |
11 |
11 |
NR |
7 |
0 |
|
2006 |
C |
10 |
10 |
NR |
NR |
NR |
|
2007 |
C |
10 |
10 |
5 |
6 |
0 |
|
2007 |
C |
9 |
9 |
NR |
NR |
NR |
|
2007 |
C |
7 |
7 |
4 |
0 |
1 |
|
2007 |
C |
6 |
5 |
2 |
3 |
0 |
|
2007 |
C |
31 |
30 |
4 |
18 |
1 |
|
2007 |
C |
16 |
13 |
0 |
7 |
0 |
|
| Total | 137 |
120 |
25 |
46 |
4 |
||
| % | 87,591241 |
18,2481752 |
|||||
| RITUXIMAB | 2002 |
D |
1 |
1 |
0 |
0 |
0 |
2003 |
D |
1 |
1 |
0 |
0 |
0 |
|
2003 |
D |
1 |
1 |
0 |
0 |
0 |
|
2003 |
D |
2 |
2 |
0 |
1 |
0 |
|
2003 |
D |
1 |
1 |
0 |
0 |
0 |
|
2004 |
D |
4 |
4 |
0 |
1 |
0 |
|
2004 |
D |
2 |
2 |
1 |
0 |
0 |
|
2005 |
D |
5 |
5 |
1 |
0 |
0 |
|
2005 |
D |
1 |
0 |
0 |
0 |
0 |
|
2005 |
D |
1 |
1 |
0 |
0 |
0 |
|
2005 |
D |
1 |
1 |
0 |
0 |
0 |
|
2006 |
D |
1 |
1 |
0 |
0 |
0 |
|
2006 |
D |
5 |
5 |
0 |
0 |
0 |
|
2006 |
D |
1 |
1 |
1 |
0 |
0 |
|
2006 |
D |
1 |
1 |
0 |
0 |
0 |
|
2006 |
D |
1 |
1 |
0 |
0 |
0 |
|
2006 |
D |
2 |
2 |
0 |
0 |
0 |
|
2006 |
D |
1 |
1 |
0 |
0 |
0 |
|
2007 |
D |
1 |
1 |
1 |
0 |
0 |
|
2007 |
D |
1 |
1 |
1 |
0 |
1 |
|
2007 |
D |
1 |
1 |
1 |
0 |
0 |
|
| Total | 35 |
34 |
6 |
2 |
1 |
||
| % | 97,142857 |
17,1428571 |
|||||
| ANAKINRA | 2004 |
D |
3 |
1 |
0 |
1 |
0 |
2005 |
D |
4 |
4 |
3 |
3 |
0 |
|
| Total | 7 |
5 |
3 |
4 |
0 |
||
| ETANERCEPT | 2006 |
D |
1 |
1 |
0 |
1 |
0 |
2006 |
D |
1 |
1 |
0 |
1 |
0 |
|
2007 |
D |
1 |
1 |
0 |
0 |
0 |
|
| Total | 3 |
3 |
0 |
2 |
0 |
||
| OCRELIZUMAB | 2006 |
D |
1 |
1 |
1 |
0 |
0 |
| Total | 1 |
1 |
1 |
0 |
0 |
||
| EPRATUZUMAB | 2006 |
C |
14 |
14 |
10 |
0 |
0 |
| Total | 14 |
14 |
10 |
0 |
0 |
||
| EFALIZUMAB | 2006 |
D |
1 |
1 |
0 |
1 |
0 |
2007 |
C |
13 |
12 |
9 |
2 |
0 |
|
| Total | 14 |
13 |
9 |
3 |
0 |